Treatment with leukotriene D4 (LTD4), a CysLT1R ligand, activated ILC2s in vitro and in vivo, and this response could be blocked by treatment with the CysLT1R antagonist montelukast, which is used in treatment of allergic asthma [16]. The gene discussed is CYSLTR1; the disease is allergic asthma.